№ files_lp_3_process_9_26807
File format: docx
Character count: 2168
File size: 13 KB
This research paper explores the development of a 3D printer that integrates a syringe pump extruder to improve material deposition control for advanced manufacturing processes.
Year:
2023
Region / City:
N/A
Subject:
Additive Manufacturing, 3D Printing
Document Type:
Research Paper
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Researchers, Engineers, Manufacturers
Effective Date:
N/A
Date of Approval:
N/A
Date of Revisions:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2002-2003
Region / City:
Not specified
Subject:
Word VBA, Printer Control
Document Type:
Article
Organization / Institution:
Not specified
Author:
Jonathan West, MVP
Target Audience:
Users of Microsoft Word VBA
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019
Region / City:
Bhubaneswar
Subject:
Procurement of Equipment
Document Type:
Invitation for Bids (IFB)
Organization:
College of Engineering & Technology, Bhubaneswar
Author:
College of Engineering & Technology, Bhubaneswar
Target Audience:
Eligible Bidders
Validity Period:
From 22-Nov-2019 to 22-Dec-2019
Approval Date:
21-Nov-2019
Amendment Date:
NA
Year:
2021
Region / City:
Suwanee (USA)
Topic:
SMT Automation
Document Type:
Press Release
Organization / Institution:
ASM Pacific Technology
Author:
ASM Assembly Systems GmbH & Co. KG
Target Audience:
Electronics Manufacturers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual Description:
Press release detailing the features and specifications of the DEK TQ stencil printer for SMT automation.
Year:
2023
Region / City:
N/A
Theme:
Receipt printer control codes
Document type:
Technical specifications
Organization / Institution:
Citizen, Epson, Bixolon, etc.
Author:
N/A
Target audience:
Engineers, Technicians
Period of validity:
N/A
Date of approval:
N/A
Date of changes:
N/A
Document Version:
2.0 (October 2021)
Year:
2021
Region / City:
Global
Subject:
Software Upgrade Instructions
Document Type:
Installation Manual
Organization:
Xerox Corporation
Author:
Xerox Corporation
Target Audience:
System Administrators
Period of Validity:
Indefinite
Approval Date:
October 2021
Modification Date:
Not specified
Software Version:
2.0
Device Models:
Xerox® AltaLink® C8100, B8100
Instructions:
Embedded Web Server Software Upgrade
Upgrade Procedure:
Software Upgrade Utility, Manual Upgrade
Required Software Versions:
105.xxx.xxx.xxxxx, 111.xxx.xxx.xxxxx, 113.xxx.xxx.xxxxx
System Requirements:
Network connectivity, administrator access
Note:
Context Description
Year:
Not specified
Region / city:
Not specified
Topic:
Office Equipment Specifications
Document type:
Technical Specification
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Bidders, suppliers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Document Code:
WHS42
Document Type:
University Risk Management Checklist
Subject:
3D Printer Hazard Identification and Risk Control
Institutional Context:
University Workplace Health and Safety
Related Standard:
SafeWork SA Risk Assessment Matrix April 2015
Hazard Categories:
Entrapment/Entanglement; Electric Shock; Heat; Noise; Fumes/Ultrafine Particles; Chemicals; Fire; Machine Tipping
Risk Assessment Method:
Risk Severity/Consequence and Likelihood Matrix
Risk Rating Levels:
High; Medium; Low; Very Low
Required Consultation:
User and Supervisor
Record Keeping:
Retained locally on SharePoint or shared drive for audit purposes
Control Measures Referenced:
Enclosed systems; Training; Standard Operating Procedures (SOP); Electrical Inspection Test & Tag; HEPA filtration; Ventilation; Safety Data Sheets (SDS); Personal Protective Equipment (PPE)
Review Requirement:
Regular review of implemented risk controls
Year:
Not specified
Region / City:
Not specified
Subject:
Tender process for 3D printer procurement
Document Type:
FAQ
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Suppliers, Tender Bidders
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year of assessment:
2022
Revision date:
March 2018
Assessment date:
October 2022
Review date:
—
Location:
SSERC, 2 Pitreavie Court, South Pitreavie Business Park, Dunfermline KY11 8UU
Department:
School laboratory
Activity:
Use of 3D Printers with polymer-based materials
Type of document:
Risk assessment
Author:
SSERC Health and Safety Team
Target audience:
Learners and staff using 3D printers
Hazards identified:
Incorrect use, fumes, dust, burns, fire, ingestion, UV/laser exposure, entanglement, trip hazards, electrical hazards
Control measures:
Training, supervision, ventilation, personal protective equipment, shielding, machine guarding, safe handling procedures
Materials involved:
Polymers, solvents, UV/laser light
Year:
2024
Region / City:
Australia
Topic:
Immunization, Respiratory Syncytial Virus (RSV), Vaccines
Document Type:
Submission
Organization:
SANOFI-AVENTIS AUSTRALIA PTY LTD
Author:
Not specified
Target Audience:
Healthcare professionals, policy makers, immunization program administrators
Period of validity:
From 2024
Approval Date:
24 November 2023
Date of Changes:
17 January 2025
Date of Submission:
7 March 2024
Note:
Contextual Description
DUPILUMAB, 300 mg in 2 mL single use pre-filled syringe, Dupixent®, Sanofi-Aventis Australia Pty Ltd
Year:
2023
Region / City:
Australia
Subject:
Atopic dermatitis treatment
Document type:
Application resubmission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Type of document:
Pharmaceutical Benefits Advisory Committee (PBAC) submission and assessment report
Medicine:
Aripiprazole long-acting injectable (AOM)
Dosage forms/strengths:
Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe; Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe
Brand:
Abilify Maintena
Sponsor:
Lundbeck Australia Pty Ltd
Purpose of submission:
Request for General Schedule Authority Required (STREAMLINED) PBS listing of AOM pre-filled syringe dose form
Indication:
Treatment of schizophrenia
Comparator:
AOM modified release injection vial kit (therapeutic vial kits)
Regulatory status:
TGA registered 7 May 2018 for acute and maintenance treatment of schizophrenia in adults and maintenance treatment of bipolar I disorder (monotherapy)
Previous PBAC consideration:
400 mg AOM PFS recommended July 2018; recommendation rescinded March 2023
Pricing basis:
Cost-minimisation versus AOM vial kit with equivalent pricing (no price premium)
Price levels referenced:
DPMQ, PTP, AEMP (current as of 1 June 2025)
Estimated PBS usage:
400,000 to <500,000 scripts over first six years (Year 1 10,000–<20,000; Year 6 100,457)
Indication listing conditions:
Authority Required (Streamlined); prescriber types include medical practitioners and nurse practitioners; general schedule (Code GE)
Year:
2021
Region / City:
Australia
Topic:
Pharmaceutical Submission
Document Type:
Regulatory Submission
Agency / Institution:
PBAC
Author:
CELLTRION HEALTHCARE AUSTRALIA PTY LTD
Target Audience:
Healthcare professionals, regulatory authorities
Effective Period:
2021 and ongoing
Approval Date:
25 August 2021
Date of Changes:
March 2022
Year:
2024
Region / City:
Australia
Topic:
Medical submission for listing of Aripiprazole 2-monthly injection
Document Type:
Submission for drug listing
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Lundbeck Australia Pty Ltd
Target Audience:
Healthcare professionals, regulatory bodies
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Background:
The submission requested a General Schedule Authority Required (Telephone/Online) listing of a new form of adrenaline (epinephrine) acid tartrate 150 micrograms/0.15 mL autoinjector (AI) (Jext® Junior (Jr)) and 300 micrograms/0.3 mL AI (Jext®) under the same circumstances as the currently listed adrenaline (epinephrine) 150 microgram/0.3 mL AI (EpiPen® Jr and Anapen® Jr 150) and 300 microgram/0.3 mL AI (EpiPen® and Anapen® 300).
Year:
2022
Region / city:
Australia
Theme:
Rheumatoid Arthritis, Pharmaceutical submission
Document type:
Submission for PBS listing
Organization / institution:
Celltrion Healthcare Australia Pty Ltd
Author:
Celltrion Healthcare Australia Pty Ltd
Target audience:
Health professionals, regulators
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2022
Region / City:
Australia
Topic:
Medicinal Product Submission
Document Type:
Submission for Pharmaceutical Listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Healthcare professionals, policy makers
Period of Validity:
Not specified
Approval Date:
10 August 2022
Date of Changes:
Not specified
Year:
2021
Region / City:
Australia
Topic:
Atopic dermatitis treatment, medication submission
Document Type:
Submission report
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Sanofi-Aventis
Target Audience:
Medical professionals, regulatory authorities
Action Period:
Ongoing treatment evaluation
Approval Date:
17 August 2021
Modification Date:
Not specified
Background:
Dupilumab registration history
Clinical Claim:
Dupilumab has superior efficacy compared to standard care for children with severe atopic dermatitis
Episodicity:
Chronic
Severity:
Severe
Condition:
Atopic dermatitis
PBS Indication:
Chronic severe atopic dermatitis
Prescriber Type:
Medical practitioners, dermatologists, clinical immunologists
Treatment Phase:
Initial, continuing
Population Criteria:
Children aged 6 to 11 years, specific weight ranges
Comparator:
Placebo
Outcomes:
EASI-75, IGA 0 or 1 at Week 16, improvement in itch score
Dosing:
Tiered by body weight
Cost:
$1,754.28–$3,380.91
Price:
Published price for maximum quantity
Form:
Pre-filled syringe
Medical Information:
Dupilumab 300 mg/2 mL, 200 mg/1.14 mL
Note:
Comparator
Standard of care (Placebo)
Source:
PBAC submission
Year:
2022
Region / City:
Australia
Topic:
Pharmaceutical submission
Document type:
Submission
Agency / Institution:
PBAC
Author:
Janssen-Cilag Pty Ltd
Target audience:
Healthcare professionals, pharmaceutical regulators
Period of validity:
N/A
Approval date:
May 2020
Date of last update:
March 2022
Context:
This document is a pharmaceutical submission requesting PBS listing for ustekinumab in the treatment of moderate to severe ulcerative colitis.
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.